Bisphosphonates: Pharmacology, mechanisms of action and clinical uses

Osteoporosis International

Volumn 9, Issue SUPPL. 2, 1999, Pages

  Russell, R G G ^a   Croucher, P I ^a   Rogers, M J ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; MEVALONIC ACID; PROTEIN;

ACUTE PHASE RESPONSE; APOPTOSIS; BONE CELL; CONFERENCE PAPER; DRUG UPTAKE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; OSTEOCLAST; OSTEOPOROSIS; PRENYLATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

APOPTOSIS; BONE AND BONES; BONE RESORPTION; CHILD; DIGESTIVE SYSTEM; DIPHOSPHONATES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; OSTEOCLASTS; OSTEOPOROSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032942599     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/PL00004164     Document Type: Conference Paper

References (127)

1. Bijvoet O, Fleisch H, Canfield RE, Russell RGG, editors. Bisphosphonates on bone. Amsterdam: Elsevier, 1995.
2. Ebetino FH, Francis MD, Rogers MJ, Russell RGG. Etidronate. Mechanisms of action of etidronate and other bisphosphonates. Rev Contemp Pharmacol 1998;9:233-43.
3. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998;19:80-100.
4. Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient, 3rd ed. New York: Parthenon Publishing, 1997.
5. Francis RM. Oral bisphosphonates in the treatment of osteoporosis: a review. Curr Ther Res 1998;56:831-51.
6. Papapoulos SE. Pharmacodynamics of bisphosphonates in man. In: Bijvoct O, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosphonates on bone. Amsterdam: Elsevier Science, 1995: chap 15.
7. Rogers MJ, Watts DJ, Russell R.G.G. Overview of bisphosphonates. Cancer 1997;80:1652-69.
8. Russell RGG, Rogers MJ. Introduction to bisphosphonates and the clinical pharmacology of alendronate. Br J Rheumatol 1997;36(Suppl):10-14.
9. Johnson S, Johnson FN, editors Etidronate in osteoporosis. Rev Contemp Pharmacol 1998;9:225-92.
10. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone Miner Res 1994;8:265-306.
11. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drug Exp Clin Res 1989;15:389-96.
12. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969;165:1264-6.
13. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
14. Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966;212:901-3.
15. Russell RGG. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet 1965;II:461-4.
16. Russell RGG, Bisaz S, Donath A, Morgan DB, Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J Clin Invest 1971;50:961-9.
17. Fleisch H, Russell RGG, Bisaz S, Muhlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro ; and on aortic and kidney calcification in vivo. Eur J Clin Invest 1970;1:12-8.
18. Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 1970;6:83-196.
19. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 1973;11:196-214.
20. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int 1986;38:342-9.
21. Ebrahimpour A, Francis MD. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosphonates on bone. Amsterdam: Elsevier 1995.
22. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
23. Ebetino FH, Bayless AV, Amburgey J, Ibbotson KJ, Dansereau S, Ebrahimpour A. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon 1996;109/110:217-20.
24. Van Beek E, Hoekstra M, Van der Ruit M, Löwik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res 1994;9:1875-82.
25. van Beek E, Lowik C, Oue I, Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 1996;11:1492-7.
26. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce, BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
27. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991;88:2095-105.
28. Hughes DE, MacDonald BR, Russell RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 1989;83:1930-5.
29. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995;17:137-44.
30. Sahni M, Guenther H, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.
31. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997;12:869-79.
32. 3H-etidronate in rat and mouse bones. Bone 1996;19:281-90.
33. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995;16:235-45.
34. 2MBP-coated bone. Bone Miner 1998;6:33-43.
35. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990;5:31-40.
36. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, et al. Alendronate inhibition of protein tyrosine phosphatase activity. Proc Natl Acad Sci USA 1995;93:3068-73.
37. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatases: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res 1996;11:535-43.
38. Olpas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, eta al. Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem Pharmacol 1997;54:721-7.
39. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1997;20:399-404.
40. + ATPase. J Bone Miner Res 1996;11:1498-507.
41. Carano A, Teitelbaum SA, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990;85:456-61.
42. Zimolo Z, Wesolowski G, Rodan, GA. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest 1995;96:2277-83.
43. Felix R, Russell RGG, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 1976;429:429-38.
44. Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 1987;8:179-89.
45. Selander KS, Mönkkönen J, Karhukorpi E-K. Härkönen P, Hannuniemi R, Väänänen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-38.
46. Rogers MJ, Chilton KM, Coxon F, Lawry J, Smith MO, Suri S, et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells by a nitric-oxide-independent mechanism. J Bone Miner Res 1996;11:1482-91.
47. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PJ. Bisphosphonates induce apoptosis in human myeloma cells: a novel anti-tumour activity. Br J Haematol 1997;98:665-72
48. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-9.
49. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78.
50. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Wil Thesing C, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986;1:27-39.
51. Löwik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groot H, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 1988;3:185-92.
52. Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 1988;4:775-81.
53. Niskikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures Bone 1996;18:9-14.
54. Yu X, Scholler J, Foged NT. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 1996;19:339-45.
55. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-33.
56. Rogers MJ, Watts DJ, Russell RGG, Ji X, Xiong X, Blackburn GM, et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res 1994;9:1029-39.
57. Rogers MJ, Xiong X, Brown RJ, et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995; 47:398-402.
58. Rogers MJ, Ji X, Russell RGG, Blackburn GM, Williamson MP, Bayless AV, et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994;303:303-11.
59. Rogers M, Russell RGG, Blackburn GM, Williamson MP, Watts DJ. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992;189:414-23.
60. Rogers MJ, Brown RJ, Hodkin V, Russell RGG, Watts DJ. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996;224:863-69.
61. Pelorgeas S, Martin J-P, Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. Biochem Pharmacol 1992;44:2157-63.
62. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-ßγ-dichloromethylene triphosphate, by mammalian cells in vitro. J Bone Miner Res 1996;12:1358-67.
63. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chrom B 1997;704:187-95.
64. Rogers MJ, Xiong X, Ji X, Mönkkönen J, Russell RGG, Blackburn GM, et al. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res 1997;14:625-30.
65. Amin D, Cornell SA, Perrone MH, Bilder GE. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res 1996;46:759-62.
66. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992;33:1657-63.
67. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem 1996;65:241-69.
68. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-99.
69. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell 1992;70:401-10.
70. Zerial M, Stenmark H. Rab GTPases in vesicular transport. Curr Opin Cell Biol 1993;5:613-20.
71. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, et al. The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995;108:2285-92.
72. Marshall C. Protein prenylation: a mediator of protein-protein interactions. Science 1993;259:1865-66.
73. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, et al. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96:133-8.
74. Ohnuma S, Nakazawa T, Hemmi H, Hallberg A-M, Koyama T, Ogura K, et al. Conversion from farnesyl diphosphate synthase to geranylgeranyl diphosphate synthase by random chemical mutagenesis. J Biol Chem 1996;271:10087-95.
75. Pennanen N, Lapinjoki S, Urtti A, Mönkkönen J Effect of liposomal and free bisphosphonates on the IL-1b, IL-6 and TNFα secretion from RAW264 cells in vitro. Pharm Res 1995;12:916-22.
76. Makkonen N, Hirvonen MR, Teräväinen T, Savolainen K, Mönkkönen J. Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther 1996;277:1097-102.
77. Mönkkönen J, Similä J, Rogers M. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci 1998;62:95-102.
78. Nakamura M, Ando T, Abe M, Kumagai K, Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol 1996;119:205-12.
79. Van Rooijen N, Kors N. Effects of intracellular diphosphonates on cells of the mononuclear system: in vivo effects of liposome-encapsulated diphosphonates on different macrophage subpopulations in the spleen. Calcif Tiss Int 1989;45:153-6.
80. Sauty A, Pecherstorfer M, Zimmerroth I, Fioroni P, Juillerat L, Markert M, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 1996;18:133-9.
81. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Lowik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-62.
82. Adami S, Zamberlan N. Adverse effects of bisphosphonates Drug Safety 1996;14:158-70.
83. Adami S, Bhalla AK, Dorizzi R, et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987;41:326-31.
84. Fogelman I, Bessent RG, Turner JF, Citrin DL, Boyce IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med 1978;19:270-5.
85. Francis MD, Fogelman I. 99mTc-diphosphonate uptake mechanisms on bone. In: Fogelman I, editor. Bone scanning in clinical practice. Berlin Heidelberg New York: Springer, 1987:1-6.
86. Smith R, Russell RGG, Bishop M. Diphosphonate and Paget's disease of bone. Lancet 1971;1:945-7.
87. Russell RGG, Smith R, Preston C, Walton RJ, Woods CF. Diphosphonates in Paget's disease. Lancet 1974;1:894-8.
88. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997;336:558-66.
89. Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339;357-63.
90. Mundy GR, Yoneda T. Bisphosphonates as anticancer drugs. N Engl J Med 1998;339:398-400.
91. Storm T, Thamsborg G, Steiniche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
92. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-9.
93. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
94. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41.
95. van Staa TP, Abenhain L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheum 1998;37:87-94.
96. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:381-7.
97. Saag KG, Emkey K, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
98. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;33:947-52.
99. Flesch G, Hauffe SA. Determination of the bisphosphonate pamidronate disodium in urine by pre-column derivatization with fluorescamine, high-performance liquid chromatography and fluorescence detection. J Chromatogr 1989;489:446-51.
100. Matuszewski BK. Determination of bisphosphonates in biological fluids. In: Bijvoct O, Fleisch HA, Canfield RE, Russell RGG, editors. Bisphosphonates on Bone. Amsterdam: Elsevier, 1995.
101. Powell JH, De Mark BR. Clinical pharmacokinetics of diphosphonates. In: Garattini S, editor. Bone resorption, metastasis, and diphosphonates. Monographs of the Mario Negri Institute for Pharmacological Research, Milan, Italy. Based on a symposium held June, 1984. New York: Raven Press, 1985:41-9.
102. Conrad KA, Lee SM. Clodronate kinetics and dynamics. Clin Pharmacol Ther 1981;30:114-20.
103. 14C-1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int 1984;36:108-13.
104. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, et al. Studies of the oral bioavailability of alendronate. Clin Pharmacol Ther 1995;58:288-98.
105. 14C-labeled ethylene-1-hydroxy-1,1-diphosphonate in normal and treated young rats. An autoradiographic and ultrastructural study. Toxicol Appl Pharmacol 1980;52:391-9.
106. Lin JH, Chen I-W, Duggan DE. Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate, in rats. Drug Metab Dispos 1992;20:473-8.
107. Michael WR, King WR, Wakim JM. Metabolism of disodium ethane-1-hydroxy 1-1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey. Toxicol Appl Pharmacol 1972;21:503-15.
108. 14C-clodronate in mice and rats. Pharmacol Toxicol 1988;62:51-3.
109. 14C-clodronate (dichloromethylene bisphosphonate) disodium in mice. Toxicol Appl Pharmacol 1987;89:187-292.
110. Recker RR, Saville PD. Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique. Toxicol Appl Pharmacol 1973;24:580-9.
111. Wasserman RH, Bonjour J-P. Fleisch H. Heal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) and disodium dichloromethylene diphosphonate (CI2MDP) in the chick. Experientia 1973;29:1110-1.
112. Yakatan GJ, Poynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, et al. Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982;31:402-10.
113. Fogelman I, Smith L, Mazess R, Wilson MA, Bevan JA. Absorption of oral diphosphonate in normal subjects. Clin Endocrinol 1986;24:57-62.
114. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int 1993;Suppl 3:S7-12.
115. van Staa TP. Post marketing survey with ICT-etidronate therapy. Rev Contemp Pharmacol 1998;9:277-86.
116. DeGroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;355:1016-21.
117. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.
118. Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR. The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Rel Res 1981;3:289-300.
119. Flora L, Hassing GS, Parfitt AM, et al. Comparative skeletal effects of two diphosphonates in dogs. Metab Bone Dis Rel Res 1980;2:389-407.
120. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
121. Garnero P, Shih WJ, Gineyts E, Karpf DG, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
122. Bounameaux HM, Shifferli J, Montani J-P, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1983;I:471.
123. Kanis JA, Preston CJ, Yates AJP, Percival RC, Mundy KI, Russell RGG. Effects of intravenous diphosphonates on renal function. Lancet 1983;I:1328.
124. Wiedmer WH, Zbinden AM, Trechsel U, et al. Ultrafiltrability and chromatographic properties of pyrophosphate, 1-hydroxyethylidene-1,1-bisphosphonate, and dichloromethylenebisphosphonate in aqueous and in human plasma. Calcif Tissue Int 1983;35:397-400.
125. Troehler U, Bonjour J-P, Fleisch H. Renal secretion of diphosphonates in rats. Kidney Int 1975;8:6-13.
126. Walton RJ, Russell RGG, Smith R. Changes in the renal and extra-renal handling of phosphate induced by disodium etidronate in man. Clin Sci Mol Med 1975;49:45-56.
127. Nolen GA, Buehler EV. The effects of disodium etidronate on the reproductive functions and embryogeny of albino rats and New Zealand rabbits. Toxicol Appl Pharmacol 1971;1:548-61.